Harrisson S et al. Six month interim results of MSDC-0602K in a large phase 2b NASH study demonstrate significant improvement in liver enzymes and glycemic control (NCT02784444). (Abstract PS-111)
Homologe en heterologe COVID-19-boostervaccinaties veilig en immunogeen
mrt 2022 | Vaccinatie, Virale infecties